Company intelligence / Profile preview

Vitarka Therapeutics

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

Vitarka Therapeutics is developing a modular platform for efficient cytosolic delivery of RNA-based therapeutics and peptides. Their EndoPore technology has demonstrated up to an ~80% cytosolic delivery rate in preclinical models—significantly higher than lipid nanoparticles (<1%). The platform has been validated in cell and animal disease models; the cell-binding domain has shown proof-of-concept in human clinical trials with other applications. No clinical results specific to their own pipeline have been reported yet.

Therapeutic areas: OncologyNeurology
Modalities: siRNA (small interfering RNA)ASO (antisense oligonucleotides)Peptides
Industry: Biotech

Drug pipeline

4 assets

VTK-235

Preclinical

3 more assets in the full pipeline.

Request access →

Partnerships

Collaborations with pharmaceutical companies mentioned but not named specifically; described as working with a strategic network alliance of collaborators and partners.

Beyond the preview

Go deeper on Vitarka Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vitarka Therapeutics.

Explore the full profile